Literature DB >> 12777356

Adjusting for screening history in epidemiologic studies of cancer: why, when, and how to do it.

Noel S Weiss1.   

Abstract

In epidemiologic studies of cancer, differences between exposed and nonexposed persons with regard to a history of cancer screening during the time the malignancy (or an antecedent lesion) typically is present prior to diagnosis can be a source of confounding if one of the following conditions is present: (1) the screening modality identifies premalignant changes whose treatment has the potential to prevent the cancer from developing; or (2) the number of cases included in the study would have been smaller but for the presence of screening. These situations occur commonly, arguing that consideration be given to screening history in the design (with attention to distinguishing true screening tests from those administered to persons with signs or symptoms of cancer) and analysis of epidemiologic studies of those cancers for which screening modalities are in use in the study population.

Entities:  

Mesh:

Year:  2003        PMID: 12777356     DOI: 10.1093/aje/kwg062

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  18 in total

1.  Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial.

Authors:  Garnet L Anderson; Rowan T Chlebowski; Aaron K Aragaki; Lewis H Kuller; JoAnn E Manson; Margery Gass; Elizabeth Bluhm; Stephanie Connelly; F Allan Hubbell; Dorothy Lane; Lisa Martin; Judith Ockene; Thomas Rohan; Robert Schenken; Jean Wactawski-Wende
Journal:  Lancet Oncol       Date:  2012-03-07       Impact factor: 41.316

Review 2.  Menopausal hormone therapy and breast cancer mortality: clinical implications.

Authors:  Rowan T Chlebowski; Garnet L Anderson
Journal:  Ther Adv Drug Saf       Date:  2015-04

3.  Variation in Breast Cancer-Risk Factor Associations by Method of Detection: Results From a Series of Case-Control Studies.

Authors:  Brian L Sprague; Ronald E Gangnon; John M Hampton; Kathleen M Egan; Linda J Titus; Karla Kerlikowske; Patrick L Remington; Polly A Newcomb; Amy Trentham-Dietz
Journal:  Am J Epidemiol       Date:  2015-05-05       Impact factor: 4.897

4.  Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study.

Authors:  Rowan T Chlebowski; JoAnn E Manson; Garnet L Anderson; Jane A Cauley; Aaron K Aragaki; Marcia L Stefanick; Dorothy S Lane; Karen C Johnson; Jean Wactawski-Wende; Chu Chen; Lihong Qi; Shagufta Yasmeen; Polly A Newcomb; Ross L Prentice
Journal:  J Natl Cancer Inst       Date:  2013-03-29       Impact factor: 13.506

5.  Colorectal cancer risk in relation to antidepressant medication use.

Authors:  Jessica Chubak; Denise M Boudreau; Stephen J Rulyak; Margaret T Mandelson
Journal:  Int J Cancer       Date:  2011-01-01       Impact factor: 7.396

6.  Breast cancer risk factors by mode of detection among screened women in the Cancer Prevention Study-II.

Authors:  Mia M Gaudet; Emily Deubler; W Ryan Diver; Samantha Puvanesarajah; Alpa V Patel; Ted Gansler; Mark E Sherman; Susan M Gapstur
Journal:  Breast Cancer Res Treat       Date:  2021-01-04       Impact factor: 4.872

7.  Dietary sugar/starches intake and Barrett's esophagus: a pooled analysis.

Authors:  Nan Li; Jessica Leigh Petrick; Susan Elizabeth Steck; Patrick Terrence Bradshaw; Kathleen Michele McClain; Nicole Michelle Niehoff; Lawrence Stuart Engel; Nicholas James Shaheen; Douglas Allen Corley; Thomas Leonard Vaughan; Marilie Denise Gammon
Journal:  Eur J Epidemiol       Date:  2017-09-01       Impact factor: 8.082

8.  Mammographic screening and risk factors for breast cancer.

Authors:  Nancy R Cook; Bernard A Rosner; Susan E Hankinson; Graham A Colditz
Journal:  Am J Epidemiol       Date:  2009-10-29       Impact factor: 4.897

9.  Quantifying lead-time bias in risk factor studies of cancer through simulation.

Authors:  Rick J Jansen; Bruce H Alexander; Kristin E Anderson; Timothy R Church
Journal:  Ann Epidemiol       Date:  2013-08-27       Impact factor: 3.797

10.  Thiazolidinedione therapy is not associated with increased colonic neoplasia risk in patients with diabetes mellitus.

Authors:  James D Lewis; Angela M Capra; Ninah S Achacoso; Assiamira Ferrara; Theodore R Levin; Charles P Quesenberry; Laurel A Habel
Journal:  Gastroenterology       Date:  2008-09-13       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.